Readthrough has been demonstrated in human vascular endothelial growth factor A (VEGF-A), producing an isoform that reverses the angiogenic properties of VEGF-A, is regulated by a ribosomal binding protein, and is suppressed in colon cancer cells, having direct relevance to cancer treatment (Eswarappa et al. 2014; Eswarappa and Fox 2015). This evidence concerns the gene VEGFA and colonic neoplasm.